Abstract: Described herein are antiviral silencing RNA molecules (siRNAs), pharmaceutical compositions comprising same and uses thereof for the treatment of viral infections. In embodiments the siRNAs comprises chemically modification(s) for enhanced cell penetrating abilities and/or for greater nuclease resistance. Examples of chemical modifications include substituting one or more nucleotides of a native siRNA molecule with 2?-O-Methylnucleoside, 2?-Fluoronucleoside, aminoalkyl-nucleotide, aminoethyl-nucleotide, and/or 5?-aminopropyl-2?-OMe-nucleoside. The chemically modified nucleotides may be incorporated into the P strand, the G strand or both. Other possible modifications include coupling a compound such as a spermine molecule to the 5? terminus or the 3? terminus of the siRNA.

Abstract: The present document describes extended release gastro retentive dosage form comprising a carboxylated polysaccharide and cinnamaldehyde conjugate formed via an acetal, hemiacetal or cyclic hemiacetal formed between an aldehyde group of the cinnamaldehyde and a hydroxyl group of the carboxylated polysaccharide. The document also describes extended release gastro retentive dosage form comprising an artesunate emulsion having a pH value of from about 7.5 to 7.9 and comprising an artesunate or pharmaceutically acceptable salts thereof, and stereoisomers thereof stabilized with an emulsifying agent. The document also describes the use of the dosage forms for treatment of H. Pylori infection.